All Articles

TROP2-targeting antibody–drug conjugates in breast cancer and ovarian carcinoma: therapeutic advances and resistance mechanisms

Evaluation of intracellular nucleotide pools in peripheral blood and bone marrow mononuclear cells and their association with frontline intensive chemotherapy response rates in AML patients

Extracellular vesicles shed by multidrug resistant cells contribute to the identification of SRC inhibitors as chemosensitizers in non-small cell lung cancer

Novel anti-tumor strategies: targeting the crosstalk between cancer stem cells and cancer-associated fibroblasts to resist drug resistance

Identification of antibody-drug conjugate payloads that are substrates of ATP-binding cassette drug efflux transporters

Circular RNA hsa-circ-0001030 suppresses proliferation and cisplatin tolerance in TSCC via interaction with PKM2

MicroRNAs as key regulators of cancer drug resistance: insights and future directions in chemotherapy, targeted-therapy, radiotherapy, and immunotherapy

Unraveling resistance to immune checkpoint inhibitors in HNSCC: from mechanisms to combination therapies

Disrupting resistance: novel therapeutic approaches to combat multidrug resistance in fusion-negative rhabdomyosarcoma

Osimertinib acquired resistance among patients with EGFR-mutated NSCLC: from molecular mechanisms to clinical therapeutic strategies

Overcoming cancer drug resistance through small-molecule targeting of HSP90 and HSP70

Mechanisms of resistance to antibody-drug conjugates in cancer therapy: molecular basis and therapeutic strategies

RCC1 knockdown sensitizes drug-resistant colorectal cancer to 5-fluorouracil or doxorubicin by impairing DNA repair

Novel FAK inhibitors suppress tumor growth and reverse EGFR-TKI resistance in non-small cell lung cancer

Circular RNA-based liquid biopsy: a promising approach for monitoring drug resistance in cancer

Targeting tumor-draining lymph node to overcome resistance to cancer immunotherapy: an update

Recent progress on tyrosine kinase inhibitors resistance in renal cell carcinoma: another brick in the wall?

KLF5 promotes tumor proliferation and oxaliplatin resistance via chromatin remodeling in KRAS-mutated colorectal cancer